• LAST PRICE
    6.1100
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (0.4934%)
  • Bid / Lots
    6.1000/ 1
  • Ask / Lots
    6.1100/ 2
  • Open / Previous Close
    6.0800 / 6.0800
  • Day Range
    Low 5.9500
    High 6.1200
  • 52 Week Range
    Low 3.6600
    High 9.0650
  • Volume
    52,281
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 6.08
TimeVolumeALEC
09:32 ET32336.12
09:38 ET3006.07
09:41 ET2006.065
09:43 ET3006.05
09:50 ET40006.039
09:52 ET3006.04
09:54 ET2006.04
09:56 ET8505.99
09:57 ET2005.99
09:59 ET23225.9801
10:01 ET6005.98
10:03 ET2005.98
10:06 ET4006
10:08 ET7735.98
10:10 ET7745.97
10:12 ET5325.96
10:14 ET3005.97
10:15 ET5005.96
10:17 ET5755.96
10:19 ET2005.96
10:24 ET5005.98
10:26 ET11755.99
10:28 ET2625.99
10:30 ET2005.99
10:32 ET2005.99
10:33 ET4005.99
10:35 ET13206.02
10:39 ET4006.03
10:42 ET1006.02
10:46 ET5006.03
10:50 ET2076.04
10:51 ET1436.05
10:53 ET3496.04
10:55 ET2006.06
10:57 ET3006.05
11:02 ET1006.03
11:08 ET50006.0493
11:09 ET13846.05
11:11 ET1006.06
11:13 ET9706.06
11:24 ET17626.09
11:27 ET11006.085
11:29 ET28626.08
11:31 ET8356.1
11:33 ET1006.1
11:36 ET2006.11
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALEC
Alector Inc
582.2M
-3.9x
---
United StatesEDIT
Editas Medicine Inc
608.7M
-3.6x
---
United StatesURGN
Urogen Pharma Ltd
510.5M
-4.0x
---
United StatesYMAB
Y-mAbs Therapeutics Inc
722.3M
-33.2x
---
United StatesNRIX
Nurix Therapeutics Inc
710.9M
-5.5x
---
United StatesWVE
WAVE Life Sciences Ltd
738.6M
-11.1x
---
As of 2024-03-28

Company Information

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Contact Information

Headquarters
131 OYSTER POINT BLVD., SUITE 600SOUTH SAN FRANCISCO, CA, United States 94080
Phone
415-231-5660
Fax
302-655-5049

Executives

President, Head - Research and Development
Saraswati Kenkaremitra
Chief Executive Officer, Co-Founder, Director
Arnon Rosenthal
Chief Financial Officer
Marc Grasso
Chief Medical Officer
Gary Romano
Lead Independent Director
Louis Lavigne

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$582.2M
Revenue (TTM)
$97.1M
Shares Outstanding
95.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.80
EPS
$-1.56
Book Value
$1.58
P/E Ratio
-3.9x
Price/Sales (TTM)
6.0
Price/Cash Flow (TTM)
---
Operating Margin
-156.33%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.